Madrigal Pharmaceuticals
MDGL
92 hedge funds and large institutions have $167M invested in Madrigal Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
12% more funds holding
Funds holding: 82 → 92 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less capital invested
Capital invested by funds: $213M → $167M (-$46.4M)
57% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $2.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
+$3.58M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$1.6M |
| 3 |
Renaissance Technologies
New York
|
+$1.5M |
| 4 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$1.28M |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$1.11M |
| 2 |
SG Americas Securities
New York
|
-$1.09M |
| 3 |
NC
NBW Capital
Boston,
Massachusetts
|
-$940K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$338K |
| 5 |
Barclays
London,
United Kingdom
|
-$179K |
MDGL Hedge Fund Activity: Q3 2014 in Review
92 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2014, worth a combined $167M — down 22% from $213M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MDGL positions and 6 closed out — a net gain of 10 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was Jefferies Group, opening a new position worth an estimated $3.58M. The largest seller was D.E. Shaw & Co, cutting an estimated $1.11M.
- 92 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2014, up from 82 in Q2 2014.
- Funds reported $167M of Madrigal Pharmaceuticals stock for Q3 2014, down 22% quarter-over-quarter.
- 16 funds opened new Madrigal Pharmaceuticals positions in Q3 2014 and 6 closed out, a net change of +10 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2014 was Jefferies Group, an estimated $3.58M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2014 was D.E. Shaw & Co, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2014.